Core Viewpoint - Several companies are projecting significant increases in net profit for 2025, with some expecting growth rates exceeding 300% compared to the previous year [1] Group 1: Companies with High Profit Growth Projections - Youyou Group anticipates a net profit increase of 357%-420% for 2025 [1] - Sanofi Health expects a net profit growth of 311% for 2025 [1] - Fujilai forecasts a net profit increase of 282.17%-296.8% for 2025 [1] - Zongyi Co. predicts a net profit growth of approximately 264.05% for 2025 [1] - Aiko Optoelectronics expects a net profit increase of 262.52%-345.2% for 2025 [1] Group 2: Companies with Moderate to High Profit Growth Projections - Pulit anticipates a net profit increase of 155.76%-194.73% for 2025 [1] - Zhongxing Junye expects a net profit growth of 134.32%-173.37% for 2025 [1] - Yixin Hall forecasts a net profit increase of 127.79%-189.12% for 2025 [1] - Bangji Technology anticipates a net profit growth of 119.43%-169.3% for 2025 [1] - Hengyu Environmental expects a net profit increase of 104.14% for 2025 [1] Group 3: Companies with Lower Profit Growth Projections - Jiaokong Technology anticipates a net profit increase of 86.44% for 2025 [1] - Boya Precision expects a net profit growth of 82.68%-128.36% for 2025 [1] - Huaxin Co. forecasts a net profit increase of 77.48% for 2025 [1] - Qingdao Danone anticipates a net profit growth of 77.47%-104.36% for 2025 [1] - Shenling Environment expects a net profit increase of 77.39%-112.87% for 2025 [1] Group 4: Companies with Further Profit Growth Projections - Keli Yuan anticipates a net profit increase of 72.76%-102.20% for 2025 [1] - Lante Optics expects a net profit growth of 70.04%-81.38% for 2025 [1] - Delijia forecasts a net profit increase of approximately 52.80% for 2025 [1] - Zhongke Electric anticipates a net profit growth of 50%-70% for 2025 [1] - Junsheng Electronics expects a net profit increase of 40.56%-1.35 billion for 2025 [1] Group 5: Companies with Lower Growth Expectations - Shanghai Yanpu anticipates a net profit increase of 35.44%-55% for 2025 [1] - Guotai Group expects a net profit growth of 30%-50% for 2025 [1] - Jiuan Medical anticipates a net profit increase of 21.05%-40.83% for 2025 [1] - AVIC Chengfei expects a net profit growth of 5.47%-11.67% for 2025 [1]

Core Viewpoint - Zhongxing Junye (002772) expects a significant increase in net profit for 2025, projecting a growth of 134.32% to 173.37% year-on-year, driven by rising sales prices and increased production capacity [4] Financial Performance - The company forecasts a net profit attributable to shareholders of 300 million to 350 million yuan for 2025, with a non-recurring net profit expected to be between 269 million and 319 million yuan, reflecting a year-on-year growth of 192.57% to 247.06% [4] - Basic earnings per share are projected to be between 0.8 yuan and 0.93 yuan [4] - As of January 26, the company's price-to-earnings ratio (TTM) is approximately 17.67 to 20.62 times, with a price-to-book ratio (LF) of about 1.82 times and a price-to-sales ratio (TTM) of around 3.1 times [4] Business Operations - The main business of the company includes research, industrial cultivation, and sales of edible mushrooms [13] - The increase in profit is attributed to stable sales prices of Agaricus bisporus, increased production and sales from the Hubei Zhongxing base, and a recovery in sales prices of enoki mushrooms in the second half of the year [13] - Financial expenses have decreased by approximately 20 million yuan year-on-year due to changes in market interest rates, exchange rates, and interest capitalization [13] Historical Financial Data - Historical net profit and non-recurring net profit data shows a consistent upward trend, with projections indicating continued growth into 2025 [14] - The year-on-year growth rates for net profit and non-recurring net profit are expected to be significantly positive, indicating strong operational performance [14]

Core Viewpoint - The company expects a significant increase in net profit for 2025, with projections indicating a growth of 134.32% to 173.37% compared to the previous year, driven by improved sales prices and increased production capacity [1] Financial Performance - The estimated net profit attributable to shareholders for 2025 is between 30 million and 35 million yuan [1] - The net profit after deducting non-recurring gains and losses is projected to be between 26.85 million and 31.85 million yuan, reflecting a growth of 192.57% to 247.06% year-on-year [1] Sales and Production Factors - The increase in net profit is primarily attributed to the stable rise in sales prices of the company's Agaricus bisporus products and the full production capacity of the Hubei base project, leading to a year-on-year increase in sales volume [1] - The sales price of enoki mushrooms saw a recovery in the second half of the year, contributing positively to the overall performance [1] Financial Costs - Financial expenses decreased by approximately 20 million yuan year-on-year due to changes in market interest rates, exchange rates, and interest capitalization [1]

Core Viewpoint - Zhongxing Junye (002772) expects a net profit attributable to shareholders of 300 million to 350 million yuan for 2025, representing a year-on-year growth of 134.32% to 173.37% [1] Group 1: Financial Performance - The main reason for the performance change is the steady increase in sales prices of the company's Agaricus bisporus products, along with increased production and sales volume from the Hubei Zhongxing base project [1] - The sales price of the company's enoki mushroom products has rebounded in the second half of the year [1] - Financial expenses have decreased by approximately 20 million yuan year-on-year due to changes in market interest rates, exchange rates, and interest capitalization [1]

（文章来源：每日经济新闻） 每经AI快讯，1月26日，众兴菌业公告，预计2025年度净利润为3亿元~3.5亿元，同比增长 134.32%~173.37%。业绩变动的主要原因系：公司双孢菇产品销售价格稳中有升，因湖北众兴基地项目 满产产销量同比增加，单品经营业绩同比增长；公司金针菇产品销售价格在下半年度有所回升；同时由 于市场利率、汇率变化及利息资本化等原因财务费用同比减少约2000万元。 ...

Group 1 - The company expects a net profit attributable to shareholders of 300 million to 350 million yuan for 2025, representing a year-on-year growth of 134.32% to 173.37% [1] - The increase in net profit is primarily due to stable and rising sales prices of the company's Agaricus bisporus products, increased production and sales volume from the Hubei base project, and improved performance in single product operations [1] - The sales price of the company's enoki mushroom products has rebounded in the second half of the year, contributing to the overall profit growth [1] Group 2 - Financial expenses have decreased by approximately 20 million yuan year-on-year due to changes in market interest rates, exchange rates, and interest capitalization [1]

（记者 王晓波） 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 每经AI快讯，众兴菌业1月26日晚间发布公告称，本次利润分配方案以截至利润分配方案披露之日公司 总股本约3.93亿股扣除回购专户持有股份约1850万股后的股本约3.75亿股为基数，向全体股东每10股派 发现金红利1.5元（含税），预计本次现金分红总额为人民币约5621万元（含税）。股权登记日为2026 年2月2日。除权除息日为2026年2月3日。 ...

证券代码：002772 证券简称：众兴菌业 公告编号：2026-014 天水众兴菌业科技股份有限公司 2025 年前三季度分红派息实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、公司回购专用证券账户中的股份18,498,826股不参与2025年前三季度利润分配； 4、2025年前三季度利润分配实施后除权除息参考价=股权登记日股票收盘价 -0.1429437元/股。 天水众兴菌业科技股份有限公司（以下简称"公司"或"本公司"）2025 年前三季度利润分配方案已获 2026 年 01 月 20 日召开的 2026 年第一次临时股东 会审议通过，现将利润分配事宜公告如下： 一、股东会审议通过利润分配方案情况 1、2026 年 01 月 20 日，公司召开 2026 年第一次临时股东会审议通过了 2025 年前三季度利润分配方案 ：以截至利润分配 方案披露之日公司总股本 393,241,359股扣除回购专户持有股份18,498,826股后的股本374,742,533 股为基 数，向全体股东每 10 股派发现金红利 1.50 元（含税），预计本 ...

一、本期业绩预计情况 1、业绩预告期间：2025 年 01 月 01 日—2025 年 12 月 31 日 证券代码：002772 证券简称：众兴菌业 公告编号：2026-015 天水众兴菌业科技股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 1 / 2 息资本化等原因财务费用同比减少约 2,000 万元。 四、风险提示 本次业绩预告是公司财务部门初步测算的结果，未经会计师事务所预审计， 具体财务数据以公司 2025 年度报告为准。敬请广大投资者审慎决策，注意投资 风险。 特此公告 | 项 | 目 | | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司股东 的净利润 | | 盈利：30,000 | 万元— 35,000 | 万元 | 盈利：12,802.95 元 | 万 | | | | 比上年同期增长：134.32% | | —173.37% | | | | 扣除非经常性损益后 的净利润 | | 盈利：26,850 | 万元—3 ...

众兴菌业公告，预计2025年度净利润为3亿元-3.5亿元，同比增长134.32%-173.37%。业绩变动的主要原 因系：公司双孢菇产品销售价格稳中有升，因湖北众兴基地项目满产产销量同比增加，单品经营业绩同 比增长；公司金针菇产品销售价格在本年下半年度有所回升；同时由于市场利率、汇率变化及利息资本 化等原因财务费用同比减少约2000万元。 ...